Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

By LabMedica International staff writers
Posted on 03 Nov 2026

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. More...

However, creatinine increases in patients receiving abemaciclib for hormone receptor-positive breast cancer can be difficult to interpret and may prompt dose reductions, treatment interruptions, or additional testing. To help clarify these findings, a new study shows that baseline cystatin C measurement can distinguish abemaciclib-related creatinine changes from possible kidney damage.

Kanazawa University (Kanazawa, Japan) researchers, working with Shinshu University (Matsumoto, Japan), evaluated baseline cystatin C measurement to help interpret renal marker changes in patients receiving abemaciclib. The drug is known to raise serum creatinine, which is eliminated in part through transporter proteins in the kidney. The study suggests that this increase may reflect blocked transport rather than kidney injury.

The researchers followed 63 patients, including 62 women and one man, at Shinshu University Hospital. Creatinine increased in 62 patients, rising from a median of 0.63 to 0.85 mg/dL. Levels remained stable through 24 weeks of treatment and declined after treatment was interrupted. Among 29 patients who underwent cystatin C testing before and during treatment, the two markers moved in opposite directions in 28 patients.

This difference is relevant because cystatin C is not secreted by the same transporters as creatinine and is therefore less affected by abemaciclib. However, the markers already disagreed before treatment in 15 of the 29 patients, or 52%. The team also examined SLC47A1, the gene encoding the MATE1 transporter, and found that patients with the GG type of the rs2289669 variant tended to have a larger creatinine increase. This exploratory finding requires confirmation in larger studies. The study was published in Clinical Pharmacology & Therapeutics.

“When creatinine rises after starting abemaciclib, it does not necessarily mean the kidneys are failing. What surprised us was that, in about half of the patients we could examine, creatinine and cystatin C already disagreed before treatment began. We therefore recommend measuring cystatin C at baseline, so that each patient has a personal reference point and can stay on an effective therapy without unnecessary dose reductions or interruptions,” said Hiroaki Watanabe, assistant professor, Faculty of Pharmacy, Kanazawa University.

Related Links
Kanazawa University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.